The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction scores, as well as less glycemic variability compared to insulin injection pens.
Marlborough, Mass.-based CeQur plans to launch Calibra’s insulin delivery device under a new name next year, the company said.
“CeQur is dedicated to simplifying insulin dosing for people with diabetes, so that they can live healthier, more satisfying lives,” CEO Robert Farra said in prepared remarks. “Clinical studies and real-world experience have shown that wearable, on-demand insulin delivery provides an ideal solution to the pervasive challenge of mealtime insulin delivery. The Calibra device is a perfect complement to PAQ, our basal and bolus insulin-infusion device. Both wearable devices provide simple, discreet, three-day insulin delivery without the barriers and discomfort created by injections.”
“This device will enable us to begin reaching the diabetes community with simple, discreet, three-day insulin delivery that will free people from having to inject multiple times per day,” Farra added.
“The Calibra device is well designed with impressive clinical results,” CeQur’s executive chairman, Eric Milledge, said. “The number of people with diabetes who require insulin will continue to grow. Given the proven benefits of this device, as well as the range of patients it can support, CeQur will improve the health and simplify the lives of these individuals.”